Literature DB >> 18311192

Dose-dependent protective effect of propofol against mitochondrial dysfunction in ischaemic/reperfused rat heart: role of cardiolipin.

H Shao1, J Li, Y Zhou, Z Ge, J Fan, Z Shao, Y Zeng.   

Abstract

BACKGROUND AND
PURPOSE: Ischaemia damages to the cardiac mitochondria by increasing generation of reactive oxygen species (ROS) and peroxidation of cardiolipin. The inhibited mitochondrial function leads to the cardiac injury during reperfusion. Propofol (2, 6-diisopropylphenol), an intravenous anaesthetic, has been shown to decrease cardiac ischaemia and reperfusion injury. In the present study, we propose that propofol protects mitochondrial function and decreases cardiac injury by prevention of cardiolipin peroxidation during ischaemia and reperfusion. EXPERIMENTAL APPROACH: After isolation of mitochondria from isolated rat heart perfused on a Langendorff model, various mitochondrial bioenergetic parameters were evaluated such as rates of mitochondrial oxygen consumption, H(2)O(2) production, complex I and III activity as well as the degree of lipid peroxidation and cardiolipin content. The action of propofol was also explored in isolated mitochondria. And the effect of cardiolipin was evaluated by fusing cardiolipin liposome with mitochondria. KEY
RESULTS: Propofol treatment had strong dose-dependent protection attenuating these parameters alterations in reperfused rat heart and isolated mitochondria. Additionally, cardiolipin treatment had the same protective effect, compared with propofol treatment at high concentration. CONCLUSIONS AND IMPLICATIONS: The protective effect of propofol appears to be due, at least in part, as a chemical uncoupler, to the interruption of the vicious circle of ROS-cardiolipin-complexes of the respiratory chain-ROS through preserving the content and integrity of cardiolipin molecules by ROS attack. These findings may provide an explanation for some of the factors responsible for cardioprotection and one approach exploring an available antioxidant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311192      PMCID: PMC2438270          DOI: 10.1038/bjp.2008.45

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  The "pro-apoptotic genies" get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes.

Authors:  V E Kagan; Y Y Tyurina; H Bayir; C T Chu; A A Kapralov; I I Vlasova; N A Belikova; V A Tyurin; A Amoscato; M Epperly; J Greenberger; S Dekosky; A A Shvedova; J Jiang
Journal:  Chem Biol Interact       Date:  2006-05-12       Impact factor: 5.192

2.  Nitric oxide inhibits peroxidase activity of cytochrome c.cardiolipin complex and blocks cardiolipin oxidation.

Authors:  Irina I Vlasova; Vladimir A Tyurin; Alexandr A Kapralov; Igor V Kurnikov; Anatoly N Osipov; Maxim V Potapovich; Detcho A Stoyanovsky; Valerian E Kagan
Journal:  J Biol Chem       Date:  2006-03-16       Impact factor: 5.157

3.  Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart.

Authors:  Y Xia; G Khatchikian; J L Zweier
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

4.  Reperfusion injury on cardiac myocytes after simulated ischemia.

Authors:  T L Vanden Hoek; Z Shao; C Li; R Zak; P T Schumacker; L B Becker
Journal:  Am J Physiol       Date:  1996-04

5.  Reactive oxygen species generated by the mitochondrial respiratory chain affect the complex III activity via cardiolipin peroxidation in beef-heart submitochondrial particles.

Authors:  G Paradies; G Petrosillo; M Pistolese; F M Ruggiero
Journal:  Mitochondrion       Date:  2001-08       Impact factor: 4.160

6.  Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors.

Authors:  Valerian E Kagan; Vladimir A Tyurin; Jianfei Jiang; Yulia Y Tyurina; Vladimir B Ritov; Andrew A Amoscato; Anatoly N Osipov; Natalia A Belikova; Alexandr A Kapralov; Vidisha Kini; Irina I Vlasova; Qing Zhao; Meimei Zou; Peter Di; Dimitry A Svistunenko; Igor V Kurnikov; Gregory G Borisenko
Journal:  Nat Chem Biol       Date:  2005-08-14       Impact factor: 15.040

7.  Propofol attenuates oxidant-induced acute lung injury in an isolated perfused rabbit-lung model.

Authors:  Masato Yumoto; Osamu Nishida; Fujio Nakamura; Hirotada Katsuya
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

8.  Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin.

Authors:  Giuseppe Paradies; Giuseppe Petrosillo; Marilva Pistolese; Nicola Di Venosa; Antonio Federici; Francesca Maria Ruggiero
Journal:  Circ Res       Date:  2003-12-01       Impact factor: 17.367

9.  Xanthine oxidase as a source of free radical damage in myocardial ischemia.

Authors:  D E Chambers; D A Parks; G Patterson; R Roy; J M McCord; S Yoshida; L F Parmley; J M Downey
Journal:  J Mol Cell Cardiol       Date:  1985-02       Impact factor: 5.000

10.  The relationship between oxygen radical generation and impairment of myocardial energy metabolism following post-ischemic reperfusion.

Authors:  G Ambrosio; J L Zweier; J T Flaherty
Journal:  J Mol Cell Cardiol       Date:  1991-12       Impact factor: 5.000

View more
  20 in total

1.  Propofol Prevents Oxidative Stress by Decreasing the Ischemic Accumulation of Succinate in Focal Cerebral Ischemia-Reperfusion Injury.

Authors:  Wei Yu; Dapeng Gao; Wen Jin; Siliang Liu; Sihua Qi
Journal:  Neurochem Res       Date:  2017-11-22       Impact factor: 3.996

2.  Molecular imaging of intracellular drug-membrane aggregate formation.

Authors:  Jason Baik; Gus R Rosania
Journal:  Mol Pharm       Date:  2011-08-12       Impact factor: 4.939

3.  Effects of propofol on myocardial ischemia-reperfusion injury in rats with type-2 diabetes mellitus.

Authors:  Ying Wang; Xiuru Qi; Chunliang Wang; Danning Zhao; Hongjie Wang; Jianxin Zhang
Journal:  Biomed Rep       Date:  2016-11-09

Review 4.  Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders: a review of theoretical concerns and clinical experiences in 28 patients.

Authors:  Yiouli P Ktena; Trygg Ramstad; Eva H Baker; Jennifer L Sloan; Andrew J Mannes; Irini Manoli; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2015-05-19       Impact factor: 4.982

5.  Propofol Protects Rats and Human Alveolar Epithelial Cells Against Lipopolysaccharide-Induced Acute Lung Injury via Inhibiting HMGB1 Expression.

Authors:  Xiaoyan Wang; Chengxiao Liu; Gongming Wang
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

6.  Mitochondrial involvement in propofol-induced cardioprotection: An in vitro study in human myocardium.

Authors:  Sandrine Lemoine; Lan Zhu; Steeve Gress; Jean-Louis Gérard; Stéphane Allouche; Jean-Luc Hanouz
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-08

7.  Propofol improves recovery of the isolated working hypertrophic heart from ischaemia-reperfusion.

Authors:  Nicola King; Madj Al Shaama; M-Saadeh Suleiman
Journal:  Pflugers Arch       Date:  2012-09-22       Impact factor: 3.657

Review 8.  Evolution of cytochrome bc complexes: from membrane-anchored dehydrogenases of ancient bacteria to triggers of apoptosis in vertebrates.

Authors:  Daria V Dibrova; Dmitry A Cherepanov; Michael Y Galperin; Vladimir P Skulachev; Armen Y Mulkidjanian
Journal:  Biochim Biophys Acta       Date:  2013-07-19

9.  Cardioprotective efficacy depends critically on pharmacological dose, duration of ischaemia, health status of animals and choice of anaesthetic regimen: a case study with folic acid.

Authors:  Coert J Zuurbier; Andre Heinen; Anneke Koeman; Roy Stuifbergen; Theodorus B M Hakvoort; Nina C Weber; Markus W Hollmann
Journal:  J Transl Med       Date:  2014-11-29       Impact factor: 5.531

10.  Propofol and magnesium attenuate isoflurane-induced caspase-3 activation via inhibiting mitochondrial permeability transition pore.

Authors:  Yiying Zhang; Yuanlin Dong; Zhipeng Xu; Zhongcong Xie
Journal:  Med Gas Res       Date:  2012-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.